921 related articles for article (PubMed ID: 15386591)
41. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 alter mitochondrial morphology during lytic replication.
LaJeunesse DR; Brooks K; Adamson AL
Biochem Biophys Res Commun; 2005 Jul; 333(2):438-42. PubMed ID: 15950179
[TBL] [Abstract][Full Text] [Related]
42. EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection.
van Gent M; Griffin BD; Berkhoff EG; van Leeuwen D; Boer IG; Buisson M; Hartgers FC; Burmeister WP; Wiertz EJ; Ressing ME
J Immunol; 2011 Feb; 186(3):1694-702. PubMed ID: 21191071
[TBL] [Abstract][Full Text] [Related]
43. Productive infection of Epstein-Barr virus (EBV) in EBV-genome-positive epithelial cell lines (GT38 and GT39) derived from gastric tissues.
Takasaka N; Tajima M; Okinaga K; Satoh Y; Hoshikawa Y; Katsumoto T; Kurata T; Sairenji T
Virology; 1998 Aug; 247(2):152-9. PubMed ID: 9705908
[TBL] [Abstract][Full Text] [Related]
44. Quantitative CSF PCR in Epstein-Barr virus infections of the central nervous system.
Weinberg A; Li S; Palmer M; Tyler KL
Ann Neurol; 2002 Nov; 52(5):543-8. PubMed ID: 12402250
[TBL] [Abstract][Full Text] [Related]
45. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.
Feng WH; Cohen JI; Fischer S; Li L; Sneller M; Goldbach-Mansky R; Raab-Traub N; Delecluse HJ; Kenney SC
J Natl Cancer Inst; 2004 Nov; 96(22):1691-702. PubMed ID: 15547182
[TBL] [Abstract][Full Text] [Related]
46. Nuclear factor-Y and Epstein Barr virus in nasopharyngeal cancer.
Chia MC; Leung A; Krushel T; Alajez NM; Lo KW; Busson P; Klamut HJ; Bastianutto C; Liu FF
Clin Cancer Res; 2008 Feb; 14(4):984-94. PubMed ID: 18281530
[TBL] [Abstract][Full Text] [Related]
47. Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1.
Adler B; Schaadt E; Kempkes B; Zimber-Strobl U; Baier B; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Jan; 99(1):437-42. PubMed ID: 11752411
[TBL] [Abstract][Full Text] [Related]
48. Detection of specific lytic and latent transcripts can help to predict the status of Epstein-Barr virus infection in transplant recipients with high virus load.
Zawilinska B; Kosinska A; Lenart M; Kopec J; Piatkowska-Jakubas B; Skotnicki A; Kosz-Vnenchak M
Acta Biochim Pol; 2008; 55(4):693-9. PubMed ID: 19015775
[TBL] [Abstract][Full Text] [Related]
49. Regulation of the expression of the Epstein-Barr virus early gene BFRF1.
Granato M; Farina A; Gonnella R; Santarelli R; Frati L; Faggioni A; Angeloni A
Virology; 2006 Mar; 347(1):109-16. PubMed ID: 16406456
[TBL] [Abstract][Full Text] [Related]
50. NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells.
Liu SF; Wang H; Lin XC; Xiang H; Deng XY; Li W; Tang M; Cao Y
Cell Biol Int; 2008 Aug; 32(8):1006-13. PubMed ID: 18579417
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of Epstein-Barr virus replication by small interfering RNA targeting the Epstein-Barr virus protease gene.
Larrat S; Morand P; Bas A; Vigne S; Crance JM; Boyer V; Nicod S; Grossi L; Buisson M; Burmeister WP; Seigneurin JM; Germi R
Antivir Ther; 2009; 14(5):655-62. PubMed ID: 19704168
[TBL] [Abstract][Full Text] [Related]
52. [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?].
Beck Z; Illés A; Keresztes K; Bessenyei B; Szöllosi Z; Kis A; Oláh E
Orv Hetil; 2006 Aug; 147(33):1539-44. PubMed ID: 17037676
[TBL] [Abstract][Full Text] [Related]
53. Induction of the early growth response 1 gene by Epstein-Barr virus lytic transactivator Zta.
Chang Y; Lee HH; Chen YT; Lu J; Wu SY; Chen CW; Takada K; Tsai CH
J Virol; 2006 Aug; 80(15):7748-55. PubMed ID: 16840354
[TBL] [Abstract][Full Text] [Related]
54. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Delecluse HJ; Feederle R; Behrends U; Mautner J
Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
[TBL] [Abstract][Full Text] [Related]
55. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia.
Niller HH; Wolf H; Minarovits J
Semin Cancer Biol; 2009 Jun; 19(3):158-64. PubMed ID: 19429479
[TBL] [Abstract][Full Text] [Related]
56. [Latency vs lytic cycle of Epstein-Barr virus: regulation of a viral gene expression is the clue].
Gruffat H; Manet E; Sergeant A
Pathol Biol (Paris); 2004 Mar; 52(2):63-5. PubMed ID: 15001233
[No Abstract] [Full Text] [Related]
57. Expression of viral and human dUTPase in Epstein-Barr virus-associated diseases.
Fleischmann J; Kremmer E; Greenspan JS; Grässer FA; Niedobitek G
J Med Virol; 2002 Dec; 68(4):568-73. PubMed ID: 12376965
[TBL] [Abstract][Full Text] [Related]
58. The activation of lytic replication of Epstein-Barr virus by baculovirus-mediated gene transduction.
Wang L; Shan L; Yin J; Zhao M; Su D; Zhong J
Arch Virol; 2006 Oct; 151(10):2047-53. PubMed ID: 16673043
[TBL] [Abstract][Full Text] [Related]
59. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene.
Speck SH; Chatila T; Flemington E
Trends Microbiol; 1997 Oct; 5(10):399-405. PubMed ID: 9351176
[TBL] [Abstract][Full Text] [Related]
60. Cells lytically infected with Epstein-Barr virus are detected and separable by immunoglobulins from EBV-seropositive individuals.
Bhaduri-McIntosh S; Miller G
J Virol Methods; 2006 Oct; 137(1):103-14. PubMed ID: 16843536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
